Abstract
Objective:This subanalysis of CURRENT, an open-label, 6-month, multicenter study, assesses changes in gastrointestinal (GI) tolerability with once-monthly oral ibandronate in women who switched from once-weekly bisphosphonates and had reported GI symptoms with their previous weekly bisphosphonate regimen.Methods:Postmenopausal women currently taking a weekly bisphosphonate switched to 150 mg monthly ibandronate. At the start of the treatment phase and after 6 months of therapy, all participants completed the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q™), a validated instrument consisting of four domains: convenience, satisfaction, quality of life, and side effects. This subanalysis assessed GI tolerability in those women who reported GI symptoms at baseline in the side effects domain of OPSAT-Q™ and change in satisfaction in those who had reported stomach upset within 48 hours of taking their previous bisphosphonate at screening.Results:Of women who reported GI symptoms at baseline, >60% reported an improvement in heartburn or acid reflux after switching to monthly ibandronate. Further, >70% reported improvements in stomach upset (excluding heartburn or acid reflux). Of those women who reported stomach upset within 48 hours of taking their previous weekly bisphosphonate at screening (n = 89), >80% reported improved overall satisfaction compared with baseline. Monthly ibandronate was generally well tolerated.Conclusion:A majority of women who experienced GI tolerability issues with weekly bisphosphonates reported improvements in GI symptoms after transitioning from a weekly bisphosphonate to monthly ibandronate for 6 months.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1.Chesnut CH III, Skag A, Christiansen C, et al; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–1249.ChesnutCHIII]]SkagA]]ChristiansenC&etal;Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.J Bone Miner Res2004191241-12492.Black DM, Thompson DE. The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial. Int J Clin Pract Suppl 1999;101:46–50.BlackDM]]ThompsonDEThe effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention Trial.Int J Clin Pract Suppl199910146-503.Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282: 1344–1352.HarrisST]]WattsNB]]GenantHK&etal;Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.JAMA19992821344-13524.Rizzoli R. Long-term outcome of weekly bisphosphonates. Clin Orthop Relat Res 2006;443:61–65.RizzoliRLong-term outcome of weekly bisphosphonates.Clin Orthop Relat Res200644361-655.McClung MR. Bisphosphonates in osteoporosis: recent clinical experience. Expert Opin Pharmacother 2000;1:225–238.McClungMRBisphosphonates in osteoporosis: recent clinical experience.Expert Opin Pharmacother20001225-2386.Hamilton B, McCoy K, Taggart HT. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259–262.HamiltonB]]McCoyK]]TaggartHTTolerability and compliance with risedronate in clinical practice.Osteoporos Int200314259-2627.Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000;119:631–638.LanzaFL]]HuntRH]]ThomsonAB&etal;Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.Gastroenterology2000119631-6388.de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016–1021.de GroenPC]]LubbeDF]]HirschLJ&etal;Esophagitis associated with the use of alendronate.N Engl J Med19963351016-10219.Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Manag Care 1998;4:1377–1382.EttingerB]]PressmanA]]ScheinJClinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis.Am J Manag Care199841377-138210.Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–2082.CummingsSR]]BlackDM]]ThompsonDE&etal;Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.JAMA19982802077-208211.Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999;9:461–468.PolsHA]]FelsenbergD]]HanleyDA&etal;Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.Osteoporos Int19999461-46812.Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83–91.ReginsterJ]]MinneHW]]SorensenOH&etal;Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.Osteoporos Int20001183-9113.Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005;21:391–401.ChesnutCH]]EttingerMP]]MillerPD&etal;Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.Curr Med Res Opin200521391-40114.Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevelance of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manag Care Pharm 1998;4:488–492.EttingerB]]PressmanA]]ScheinJ&etal;Alendronate use among 812 women: prevelance of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation.J Manag Care Pharm19984488-49215.Penning-van Beest FJ, Goettsch WG, Erkens JA, et al. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236–242.Penning-van BeestFJ]]GoettschWG]]ErkensJA&etal;Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.Clin Ther200628236-24216.Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013–1022.SirisES]]HarrisST]]RosenCJ&etal;Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.Mayo Clin Proc2006811013-102217.Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002;77:1031–1043.CryerB]]BauerDCOral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?Mayo Clin Proc2002771031-104318.Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007;30:755–763.StrampelW]]EmkeyR]]CivitelliRSafety considerations with bisphosphonates for the treatment of osteoporosis.Drug Saf200730755-76319.Lanza FL. Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention. Treat Endocrinol 2002;1:37–43.LanzaFLGastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention.Treat Endocrinol2002137-4320.Koltun W, Emkey RD, Kroll R, et al. Monthly ibandronate is more tolerable than weekly alendronate—results of BALTO I and II studies. Obstet Gynecol 2007;109:98S. [abstract]21.Bonnick SL, Silverman SL, Tanner SB, et al. Patient satisfaction in postmenopausal women treated with a weekly biophosphonate transitioned to once-monthly ibandronate. J Womens Health 2009. In press.22.Flood EM, Beusterien KM, Green H, et al. Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes. 2006;4:42. Available at: http://www.hqlo.com/content/4/1/42/additional/. Accessed May 14, 2008.23.Rossini M, Bianchi G, Di Munno O, et al; Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914–921.RossiniM]]BianchiG]]Di MunnoO&etal;Treatment of Osteoporosis in clinical Practice (TOP) Study GroupDeterminants of adherence to osteoporosis treatment in clinical practice.Osteoporos Int200617914-92124.Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209–216.TostesonAN]]GroveMR]]HammondCS&etal;Early discontinuation of treatment for osteoporosis.Am J Med2003115209-21625.Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003–1008.CaroJJ]]IshakKJ]]HuybrechtsKF&etal;The impact of compliance with osteoporosis therapy on fracture rates in actual practice.Osteoporos Int2004151003-100826.Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965–968.YoodRA]]EmaniS]]ReedJI&etal;Compliance with pharmacologic therapy for osteoporosis.Osteoporos Int200314965-96827.Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000;22:1433–1442.MillerPD]]WoodsonG]]LicataAA&etal;Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms.Clin Ther2000221433-144228.Marshall JK. The gastrointestinal tolerability and safety of oral bisphosphonates. Expert Opin Drug Saf 2002;1:71–78.MarshallJKThe gastrointestinal tolerability and safety of oral bisphosphonates.Expert Opin Drug Saf2002171-78
